Psomagen Inc. and Cell Biotech Co Ltd. has signed a memorandum of understanding (MoU) to jointly strive for big data-based microbiome research and commercialization. According to the MoU, Psomagen and Cell Biotech will research microbial organisms that will show clinical efficacy in health care, as well as develop new probiotics products. Using Psomagen's big data analysis technology, they will identify potential novel drug materials and develop probiotics products specifically targeting regional, racial characteristics.